Robert A. Eckert - 19 May 2026 Form 4 Insider Report for AMGEN INC (AMGN)

Reporting relationship: Director
Issuer ticker: AMGN
Reported as of: 19 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 May 2026, 18:58:32 UTC
Prior SEC filing: 08 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert A. Eckert

Key filing fact

Robert A. Eckert filed Form 4 for AMGEN INC (AMGN) on 21 May 2026.

Key facts

This page summarizes Robert A. Eckert's Form 4 filing for AMGEN INC (AMGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 May 2026, 18:58.

Change

Previous filing in this sequence was filed on 08 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001194256 Primary reporting owner

ECKERT ROBERT

Relationship: Director
Address: ONE AMGEN CENTER DRIVE, THOUSAND OAKS
Signature: /s/ Robert A. Eckert
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMGN transaction

Common Stock

Award

Transaction value
Shares: +665
Change %: +2.6%
Price: $0.000000^*
Shares after: 26,251
Date: 19 May 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

Footnote F2

These shares include 3,943 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.